LumiThera announced that it will debut the Valeda Light Delivery System for the treatment of dry AMD in the exhibition hall at the EURETINA meeting in Vienna. It will also host a symposium on photobiomodulation (PBM) technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases” on September 20th.
“Valeda is our first commercial product and we are excited to launch at EURETINA,” Clark E. Tedford, President and CEO of LumiThera, said in a company news release. “We are also delighted to be sponsoring a symposium on PBM with four experts in the ophthalmology field. We believe the symposium will provide researchers and physicians the background, science, and patient benefits of PBM therapy and the latest on the development of the Valeda Light Delivery System for the treatment for dry AMD.”
“I have been conducting research in PBM in ocular indications for many years and LumiThera’s efforts to bring this therapy to the physicians and patients is incredible,” Janis Eells, PhD, Professor, University of Wisconsin-Milwaukee, said in the news release. “I am happy to moderate the PBM symposium and look forward to teaching others about the potential of PBM therapy in ocular disease.”
LumiThera recently presented topline data from the LIGHTSITE I study at the ARVO conference in May 2018 and has a multicenter trial in Europe planned to begin in the near term to further support clinical and anatomical benefits with the Valeda Light Delivery System. The therapy consists of a series of light-based treatments to the retinal cells, resulting in improved energy production and addressing inflammation, ischemia and metabolic dysfunction that contribute to disease.